Severe acute respiratory syndrome medical therapy

Jump to navigation Jump to search

Severe Acute Respiratory Syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Severe Acute Respiratory Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Social Impact

Case Studies

Case #1

Severe acute respiratory syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Severe acute respiratory syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Severe acute respiratory syndrome medical therapy

CDC on Severe acute respiratory syndrome medical therapy

Severe acute respiratory syndrome medical therapy in the news

Blogs on Severe acute respiratory syndrome medical therapy

Directions to Hospitals Treating Severe acute respiratory syndrome

Risk calculators and risk factors for Severe acute respiratory syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Antibiotics are ineffective. Treatment of SARS so far has been largely supportive with antipyretics, supplemental oxygen and ventilatory support as needed.

Suspected cases of SARS must be isolated, preferably in negative pressure rooms, with full barrier nursing precautions taken for any necessary contact with these patients.

There was initially anecdotal support for steroids and the antiviral drug ribavirin, but no published evidence has supported this therapy. Many clinicians now suspect that ribavirin is detrimental.

Researchers are currently testing all known antiviral treatments for other diseases including AIDS, hepatitis, influenza and others on the SARS-causing coronavirus.

There is some evidence that some of the more serious damage in SARS is due to the body's own immune system overreacting to the virus. There may be some benefit from using steroids and other immune modulating agents in the treatment of the more acute SARS patients. Research is continuing in this area.

In December 2004 it was reported that Chinese researchers had produced a SARS vaccine. It has been tested on a group of 36 volunteers, 24 of whom developed antibodies against the virus. [1]

A 2006 systematic review of all the studies done on the 2003 SARS epidemic found no evidence that antivirals, steroids or other therapies helped patients. A few suggested they caused harm.[2]


  • Severe acute respiratory distress syndrome- coronavirus infection treatment[3][4][5]
  • Preferred regimen: supportive therapy
  • Note: New therapies were studied for SARS during the last outbreaks which concluded:
  • Ribavirin ineffective and probably harmful due to haemolytic anaemia
  • Lopinavir PLUS Ritonavir is still controversial and need further investigation
  • Interferon has no benefit and its studies are inconclusive
  • Corticosteroids increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis
  • Inhaled Nitric oxide potent mediator of airway inflammation, its has improved oxygenation in some studies

References

  1. First SARS vaccine trials a success China Daily January 15, 2005
  2. SARS: Systematic Review of Treatment Effects PLoS Medicine September 2006 URL Accessed 13 September 2006
  3. Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
  4. Stockman LJ, Bellamy R, Garner P (2006). "SARS: systematic review of treatment effects". PLoS Med. 3 (9): e343. doi:10.1371/journal.pmed.0030343. PMC 1564166. PMID 16968120.
  5. Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P (2005). "Treatment and vaccines for severe acute respiratory syndrome". Lancet Infect Dis. 5 (3): 147–55. doi:10.1016/S1473-3099(05)01307-1. PMID 15766649.


Template:WikiDoc Sources